FundedIQ
Health Care

Resistell AG

Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. The rapid AST method is based on the detection of movement caused by living bacterial cells. Because the test is growth independent rapid AST, we reduce the time taken to get a result from days to minutes. Resistell provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered.

resistell.com Basel, Switzerland 11-50 employees
Total raised
$9.2M
Rounds
1
Latest
Series B
Dec 2022

Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. The rapid AST method is based on the detection of movement caused by living bacterial cells. Because the test is growth independent rapid AST, we reduce the time taken to get a result from days to minutes. Resistell provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered.

Resistell AG has raised $9.2M across 1 round. Its most recent round was a Series B of $9.2M in Dec 2022. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Dec 20, 2022
Series B
$9.2M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Resistell AG is featured in

Similar companies

Multiwave Technologies

Multiwave develops breakthrough Magnetic Resonance Imaging and Positron Emission Tomography devices. Founded in Switzerland in March 2015, Multiwave Technologies AG has its headquarters in Geneva, Switzerland and a R&D facility in France.

Venture - Series Unknown $4.5M
Oryl Photonics

Oryl Photonics develops a laboratory instrument for pharmaceutical and biotech companies that provides simple, reliable, cost-effective and sustainable solubility measurement to accelerate drug development for better and effective medicine.

Series A
Odne

Lumendo is a medtech startup that develops light-active medical fillers for elegant and time saving surgeries. The fillers allow time-saving surgery for the best patient outcome. These can be used to form implants in any cavity inside the body. Lumendo was founded on 2018 and is headquartered in Renens, Switzerland.

Series A $5.2M
Positrigo

Positrigo is a company focused on creating, manufacturing, and marketing specialized PET scanners for the brain.

Series Unknown $8.5M
Hedera Dx

Liquid biopsies offer improved treatment options for a larger number of patients. Hedera Dx is committed to expanding access to advanced cancer treatment for the next billion people. We focus on developing NGS-based liquid biopsies that can be easily implemented in clinics, allowing for non-invasive diagnosis, timely treatment decisions, and ongoing disease tracking. Our company values include innovative thinking, modern approaches, and a human-centric culture, creating a dynamic and creative work atmosphere. Visit hederadx.com to find out more about joining our team.

Series A $17.1M
Axmed

Axmed is a company that specializes in serving low and middle-income countries (LMICs), with the goal of enhancing their ability to purchase affordable, high-quality medicines. We collaborate only with reputable pharmaceutical companies and certified healthcare providers to expedite the availability of medications.

Series Unknown $5.0M
EarlySight

EarlySight was created to expedite the advancement of technology and make it accessible in clinics.

Series Unknown $480k
Clee Medical
Series Unknown $170k
Carewell
Series Unknown $170k
Scanvio

Scanvio provides gynecologists with AI-enhanced ultrasound software to accelerate the diagnosis of endometriosis, enhancing their sonography skills and advancing medical and surgical education.

Series Unknown $160k
EBAMed

EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware and software components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.

Series A $1.7M
Resmonics

Resmonics, established in October 2020 as a result of collaboration between ETH Zürich and University St. Gallen, specializes in developing a privacy-minded acoustic AI technology. This technology is designed to analyze the sound environment of a room, with a particular emphasis on identifying signs of infectious lung diseases. Through its product line, Quorum, Resmonics integrates this AI with air quality sensors and noise analysis tools to create conducive and efficient working environments.

Series Unknown $210k
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.